Development of methods for the bioanalysis of RRx-001 and metabolites

Bioanalysis

Volumn 6, Issue 7, 2014, Pages 947-956

  Scicinski, Jan ^a   Oronsky, Bryan ^a   Cooper, Vance ^b   Taylor, Michael ^c   Alexander, Mike ^b   Hadar, Rebecca ^d   Cosford, Rebecca ^e   Fleischmann, Thomas ^b   Fitch, William L ^f  

^a RadioRx Inc   (United States)

^b BASi West Coast Operations   (United States)

^c NonClinical Safety Assessment   (United States)

^d BASi West Lafayette in ^*  (United States)

^e Cosford Consulting Inc ^*  (United States)

^f STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMO 1 (3,3 DINITROAZETIDIN 1 YL)ETHANONE; ACIVICIN; ANTINEOPLASTIC AGENT; DRUG METABOLITE; GLUTATHIONE; RRX 001; UNCLASSIFIED DRUG; AZETIDINE DERIVATIVE; NITRO DERIVATIVE; RRX-001;

ANALYSIS; ARTICLE; BIOANALYSIS; BLOOD; CONTROLLED STUDY; DERIVATIZATION; DOG; DRUG CONJUGATION; DRUG DEGRADATION; ENZYMATIC DEGRADATION; ENZYME INHIBITION; GOOD LABORATORY PRACTICE; HUMAN; LIQUID CHROMATOGRAPHY; NONHUMAN; PLASMA; RAT; TANDEM MASS SPECTROMETRY; VALIDATION STUDY; ANIMAL; CALIBRATION; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; AZETIDINES; CALIBRATION; CHROMATOGRAPHY, LIQUID; DOGS; HUMANS; NITRO COMPOUNDS; RATS; TANDEM MASS SPECTROMETRY;

EID: 84900031510     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.331     Document Type: Article

References (25)

1. Radiorx, Inc., Alliant Techsystems Inc.: US7507842 (2009
2. Oronsky B, Scicinski J, Reid T, Knox S. Beyond antiangiogenesis: Vascular modulation as an anticancer therapy-A review. Transl. Oncol. 5(3), 133-140 (2012
3. Straessler N, Lesley M, Cannizzo L. Development of a safe and efficient two-step synthesis for preparing 1-bromoacetyl-3, 3-dinitroazetidine, a novel clinical anticancer candidate. Org. Process Res. Dev. 16(3), 512-517 (2012
4. Brennan P, Downie I, Langdon J, Zaki G. Emerging role of nitric oxide in cancer. Br. J. Oral Maxillofac. Surg. 37(5), 370-373 (1999
5. Muntane J, La Mata M. Nitric oxide and cancer. World J. Hepatol. 2(9), 337-344 (2010
6. Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radio- resistance: Novel strategy for cancer therapy: Nitric oxide donor as a therapeutic enhancer. Nitric Oxide 19(2), 205-216 (2008
7. Scatena R, Bottoni P, Pontoglio A, Giardina B. Pharmacological modulation of nitric oxide release: New pharmacological perspectives, potential benefits and risks. Curr. Med. Chem. 17(1), 61-73 (2009
8. Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox S. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 72(10), 2600-2608 (2012
9. Scicinski J, Oronsky B, Taylor M et al. Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent. Drug Metab. Dispos. 40(9), 1810-1816 (2012
10. Oronsky B, Reid T, Knox S, Scicinski J. The scarlet letter of alkylation: A mini review of selective alkylating agents. Transl. Oncol. 5(4), 226-229 (2012
11. Singh J, Petter R, Baillie T, Whitty A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10(4), 307-317 (2011
12. Ortega A, Mena S, Estrela J. Glutathione in cancer cell death. Cancers (Basel) 3(1), 1285-1310 (2011
13. Boyle R, Travers S. Hypoxia: Targeting the tumour. Anticancer Agents Med. Chem. 6(4), 281-286 (2006
14. Mitrea N, Leblanc A, St-Onge M, Sleno L. Assessing covalent binding of reactive drug metabolites by complete protein digestion and LC-MS analysis. Bioanalysis 2(7), 1211-1221 (2010
15. Orioli M, Aldini G, Beretta G, Facino R, Carini M. LC-ESI-MS/MS determination of 4-hydroxy-trans-2-nonenal Michael adducts with cysteine and histidine-containing peptides as early markers of oxidative stress in excitable tissues. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 827(1), 109-118 (2005
16. Rappaport S, Li H, Grigoryan H, Funk W, Williams E. Adductomics: Characterizing exposures to reactive electrophiles. Toxicol. Lett. 213(1), 83-90 (2011
17. Wen B, Fitch W. Analytical strategies for the screening and evaluation of chemically reactive drug metabolites. Expert Opin. Drug Metab. Toxicol. 5(1), 39-55 (2009
18. Blair I. Analysis of endogenous glutathione-adducts and their metabolites. Biomed. Chromatogr. 24(1), 29-38 (2009
19. Fitch W, Berry P, Tu Y et al. Identification of glutathione-derived metabolites from an IP receptor antagonist. Drug Metab. Dispos. 32(12), 1482-1490 (2004
20. Silva R, Boldt S, Costa V et al. Evaluation of GSH adducts of adrenaline in biological samples. Biomed. Chromatogr. 21(7), 670-679 (2007
21. Whitfield J. Gamma glutamyl transferase. Crit. Rev. Clin. Lab. Sci. 38(4), 263-355 (2001
22. Tso J, Bower S, Zalkin H. Mechanism of inactivation of glutamine amidotransferases by the antitumor drug L-(alpha S, 5S)-alpha-amino-3-chloro-4, 5-dihydro-5-isoxazoleacetic acid (AT-125). J. Biol. Chem. 255(14), 6734-6738 (1980
23. Smith T, Ikeda Y, Fujii J, Taniguchi N, Meister A: Different sites of acivicin binding and inactivation of gamma-glutamyl transpeptidases. Proc. Natl Acad. Sci. USA 92(6), 2360-2364 (1995
24. Wickham S, Regan N, West M et al. Inhibition of human gamma-glutamyl transpeptidase: Development of more potent, physiologically relevant, uncompetitive inhibitors. Biochem. J. 450(3), 547-557 (2013
25. Kannan R, Yi JR, Zlokovic BV, Kaplowitz N. Molecular characterization of a reduced glutathione transporter in the lens. Invest. Ophthalmol. Vis. Sci. 36, 1785-1792 (1995).